Price adjustments and better supply chain lift gross margin EBIT up 15% q-o-q is a good sign Gross m...
Sales +9% and adj. EBITA +58% vs. ABGSCe Margin expansion in both segments: Inission 8.
Taaleri's Q1 was underpinned by the strong performance of Garantia, but higher-than-expected costs w...
Q1 revenues were 3% below Refinitiv consensus and clean EBIT was 7% below.
Redeye increases its Base Case and forecasts following a strong Q1 and a record high order book.
Redeye expected a stronger Q1 performance indeed. Warranty issues still haunted the company and sale...
Redeye noterar att konkurrenten Eli Lilly har presenterat positiv top-line data med Donanemab i fas ...
Redeye looks positively upon today’s news that Genovis has teamed with ArcticZymes Technologies to b...
Nya data underbygger effekten hos nadunolimab och det är fortsatt dröjsmål i PanCAN-studien.
Freshness is facing severe headwinds... ...and now Protection was also affected Q4'22 profitability ...
God organisk omsättningsutveckling Beijer Alma redovisar ett starkt kvartal utifrån förväntningarna.
Stark tillväxt tyder på fortsatt god efterfrågan Physitrack fortsätter att växa snabbt med en total ...
Odramatiska siffror Rapporten för det första kvartalet visade på fortsatt låg försäljning som uppgic...
Redeye provides an update following Heliospectra’s Q1’23 report, where an increased gross margin, a ...
Aspo’s Q1 results were a bit lower than estimated. We find there to have been mixed development unde...
Vaisala reports its Q1 result on Friday, May 5th. Growth is foreseen, but margin improvement is yet ...
Q1: Sales 9% above, gross profit 1% above Reiterates '23 guidance: 20% y-o-y growth on midpoint Rece...
Gross margin at 46.2% due to improved market situation New 5-part instrument for veterinary use laun...
Redeye will likely increase its Base Case and forecasts following a strong Q1 report in line with pr...
Redeye comments on Stillfront’s Q1-results where the outcome was in line with expectations while the...
